9/11 and cancer: what 25 years of surveillance actually shows
Registries show a real but narrow signal: a few cancers, led by prostate and thyroid, run high in 9/11 responders, while overall cancer incidence sits at or below the rate expected.
A new class of myeloma drug was approved on a more sensitive test of remission
Zenbexus didn't have to outlive patients in a control arm to win approval — it had to clear their bone marrow of detectable disease faster. That shortcut is becoming the norm, not the exception.
Brazil's regulator approved 18 new cancer drugs in five years. The FDA approved 73.
A comparison of FDA, EMA and ANVISA decisions from 2020 to 2024 finds Brazilian approvals arriving about a year later. A second study clocks the wait for public-system financing in years, not months.